囊性纤维化且FEV1≤50%预计值患者2年内死亡或肺移植概率预后模型的开发与内部验证
该研究利用囊性纤维化基金会与器官共享联合网络(UNOS)登记数据,纳入年龄≥6岁、截至2014年12月31日FEV1≤50%预计值的囊性纤维化患者,采用LASSO方法在随机训练集中筛选预后变量,并在独立测试集中验证模型对2年内死亡或肺移植的预测效能。结果显示,FEV1每降低5%预计值(OR 1.51,95%CI 1.27-1.81)、静脉抗生素治疗的肺部急性加重次数(OR 1.35,95%CI 1.11-1.65)以及持续或夜间氧疗(OR 3.71,95%CI 1.81-7.59)与2年内死亡或肺移植显著相关。该模型预测的敏感度比(1.26,95%CI 1.02-1.54)、阳性预测值比(1.25,95%CI 1.05-1.51)和阴性预测值比(1.04,95%CI 1.01-1.07)均优于FEV1<30%预计值。在2014年服用ivacaftor的患者中,仅FEV1仍与2年内死亡或肺移植相关。
要点
- FEV1每降低5%预计值,2年内死亡或肺移植风险增加(OR 1.51,95%CI 1.27-1.81)。
- 持续或夜间氧疗者2年内死亡或肺移植风险显著升高(OR 3.71,95%CI 1.81-7.59)。
- 静脉抗生素治疗的肺部急性加重次数每增加一次,风险增加(OR 1.35,95%CI 1.11-1.65)。
- 模型预测的敏感度比(1.26,95%CI 1.02-1.54)、阳性预测值比(1.25,95%CI 1.05-1.51)和阴性预测值比(1.04,95%CI 1.01-1.07)均优于FEV1<30%预计值。
- 在2014年服用ivacaftor的患者中,仅FEV1仍与2年内死亡或肺移植相关。
适用人群与场景
- 囊性纤维化患者,年龄≥6岁,截至2014年12月31日FEV1≤50%预计值,数据来自囊性纤维化基金会与UNOS登记数据库。
研究设计与关键结果
- 研究类型为预后模型开发与内部验证,使用囊性纤维化基金会与UNOS登记数据,随机分为训练集和独立测试集。
- 在训练集中采用LASSO方法筛选变量,最终模型包含FEV1百分比预计值(每降低5%:OR 1.51,95%CI 1.27-1.81)、静脉抗生素治疗的肺部急性加重次数(OR 1.35,95%CI 1.11-1.65)和持续或夜间氧疗(OR 3.71,95%CI 1.81-7.59)。
- 在独立测试集中验证,模型预测2年内死亡或肺移植的敏感度比(1.26,95%CI 1.02-1.54)、阳性预测值比(1.25,95%CI 1.05-1.51)和阴性预测值比(1.04,95%CI 1.01-1.07)均优于FEV1<30%预计值。
- 在2014年服用ivacaftor的患者中,仅FEV1仍与2年内死亡或肺移植相关。
- 在有UNOS数据的患者中,LASSO还识别出无创通气使用、低血红蛋白、肺动脉收缩压、补充氧疗、机械通气、FEV1百分比预计值和心脏指数等额外协变量。
证据类型、等级与局限
- 证据类型:预后模型开发与内部验证研究。
- 局限:样本量小(原文述「limited by small sample size」)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Improved methods are needed to risk-stratify patients with cystic fibrosis (CF) and reduced FEV1.
RESEARCH QUESTIONS: What are the predictors of death or lung transplantation (LTx) within 2 years among patients with CF whose FEV1 ≤ 50% predicted? Do these markers similarly predict outcomes among G551D patients taking ivacaftor since 2012?
STUDY DESIGN AND METHODS: Patients with CF, age ≥ 6 years with FEV1 ≤ 50% predicted as of December 31, 2014, were identified in a data set that merged Cystic Fibrosis Foundation and United Network for Organ Sharing (UNOS) registries. The least absolute shrinkage and selection operator (LASSO) method was applied to a randomly selected training set to select important prognostic variables. Accuracy and association of the model with death or LTx with 2 years (2-year death or LTx) were validated via logistic regression on an independent test set. Sensitivity analyses explored predictors for patients with UNOS data.
RESULTS: FEV1 percent predicted (OR, 1.51 for 5% decrease; 95% CI, 1.27-1.81), number of pulmonary exacerbations treated with IV antibiotics (OR, 1.35; 95% CI, 1.11-1.65), and continuous or nocturnal oxygen (OR, 3.71; 95% CI, 1.81-7.59) were significantly associated with 2-year death or LTx. Our model predicted outcomes with greater sensitivity (ratio of sensitivity, 1.26; 95% CI, 1.02-1.54), ratio of positive predictive value (1.25; 95% CI, 1.05-1.51), and ratio of negative predictive value (1.04; 95% CI, 1.01-1.07) than FEV1 < 30% predicted. Among those taking ivacaftor in 2014, only FEV1 remained associated with 2-year death or LTx. For patients with UNOS data, LASSO identified additional covariates of interest, including noninvasive ventilation use, low hemoglobin, pulmonary arterial systolic pressure, supplemental oxygen, mechanical ventilation, FEV1 percent predicted, and cardiac index.
INTERPRETATION: Among individuals with CF and FEV1 ≤ 50% predicted, FEV1 percent predicted, oxygen therapy, and number of pulmonary exacerbations predicted 2-year death or LTx. Although limited by small sample size, only FEV1 remained predictive in patients receiving highly effective modulator therapy. Additional physiologic variables could improve prognostication in CF.
参考来源
- Ramos KJ, Hee Wai T, Stephenson AL, et al. Development and Internal Validation of a Prognostic Model of the Probability of Death or Lung Transplantation Within 2 Years for Patients With Cystic Fibrosis and FEV1 ≤ 50% Predicted. Chest. 2022. PMID: 35643116. doi:10.1016/j.chest.2022.05.021
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。